{
    "clinical_study": {
        "@rank": "38580", 
        "arm_group": {
            "arm_group_label": "Brexpiprazole", 
            "arm_group_type": "Experimental", 
            "description": "Up to 4 mg/day, once daily dose, tablets, orally"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the effects of flexibly dosed brexpiprazole\n      monotherapy in the improvement of early-episode schizophrenia through the assessment of\n      social functioning, efficacy, and tolerability.  Early-episode schizophrenia is defined as\n      episodes occurring \u2264 5 years after the onset of the first episode."
        }, 
        "brief_title": "Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria: Have a diagnosis of schizophrenia as defined by the Diagnostic and\n        Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and\n        confirmed by both the Mini International Neuropsychiatric Interview (M.I.N.I.) for\n        Schizophrenia and Psychotic Disorders Studies and an adequate clinical psychiatric\n        evaluation.\n\n          -  Had the start of their first schizophrenia episode \u2264 5 years before the time of\n             consent.\n\n          -  Are 18 to 35 years old at the time of consent (inclusive, and outpatients only).\n\n          -  Have a Positive and Negative Syndrome Scale (PANSS) Total Score of \u2264 80 at screening\n             and baseline.\n\n          -  Exhibit schizophrenia symptoms with a score \u2265 4 on the PANSS for \u22651 items related to\n             active social avoidance, emotional withdrawal, passive/apathetic social withdrawal,\n             and difficulty in abstract thinking.\n\n          -  Have a diagnosis of schizophrenia made at least 6 months prior to screening as\n             confirmed by subject, caregiver, or documented history.\n\n        Exclusion Criteria: Subjects presenting with a first episode of schizophrenia based on the\n        clinical judgment of the investigator.\n\n          -  Subjects who have been hospitalized for psychotic symptoms within the previous year.\n\n          -  Subjects with schizophrenia who are considered resistant/refractory to antipsychotic\n             treatment by history or who have a history of failure to respond to clozapine or\n             response to clozapine treatment only.\n\n          -  Subjects with a current DSM-IV-TR Axis I diagnosis other than schizophrenia,\n             including, but not limited to, schizoaffective disorder, MDD, bipolar disorder,\n             post-traumatic stress disorder, anxiety disorders, delirium, dementia, amnestic, or\n             other cognitive disorders. Also, subjects with borderline, paranoid, histrionic,\n             schizotypal, schizoid, or antisocial personality disorders.\n\n          -  Subjects experiencing acute depressive symptoms within the past 30 days, according to\n             the investigator's opinion, that require treatment with an antidepressant.\n\n          -  Subjects with clinically significant tardive dyskinesia at enrollment, as determined\n             by a score of>= 3 on Item 8 of the AIMS at screening or baseline.\n\n          -  Subjects with a score of 5 (severe akathisia) on the BARS global clinical assessment\n             of akathisia at screening or baseline.\n\n          -  Subjects who have met DSM-IV-TR criteria for substance abuse or dependence within the\n             past 180 days; including alcohol and benzodiazepines, but excluding nicotine."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "35 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "46", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013622", 
            "org_study_id": "331-13-006"
        }, 
        "intervention": {
            "arm_group_label": "Brexpiprazole", 
            "description": "Treatment (16 weeks) Up to 4 mg/day, once daily dose, tablets, orally", 
            "intervention_name": "Brexpiprazole", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "schizophrenia", 
            "Mental Disorders", 
            "Psychotic Disorders", 
            "social avoidance", 
            "emotional withdrawal", 
            "passive/apathetic", 
            "social withdrawal", 
            "antipsychotic"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Cerritos", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90703"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chula Vista", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92105"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Costa Mesa", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92626"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Long Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90806"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oakland", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94612"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oceanside", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92056"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pico Rivera", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90660"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Riverside", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92506"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92123"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92102"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Ana", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92705"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torrance", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90502"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort lauderdale", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33334"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hoffman Estates", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60169"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lake Charles", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70629"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14618"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19139"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38119"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75243"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75231"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77007"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Protocol 331-13-006: An Exploratory, Multicenter, Open-label, Monotherapy, Flexible-dose Brexpiprazole (OPC 34712) Trial in Adults With Early Episode Schizophrenia", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "PANSS Total Score change from baseline to Week 16", 
            "safety_issue": "No", 
            "time_frame": "Week 16"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013622"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline to Week 16 scores in the following negative scale items: active social avoidance, emotional withdrawal, passive/apathetic social withdrawal, and difficulty in abstract thinking", 
                "safety_issue": "No", 
                "time_frame": "Week 16"
            }, 
            {
                "measure": "CGI-S score change from baseline to Week 16", 
                "safety_issue": "No", 
                "time_frame": "Week 16"
            }, 
            {
                "measure": "CGI-I score at Week 16", 
                "safety_issue": "No", 
                "time_frame": "Week 16"
            }, 
            {
                "measure": "Response rates (defined as CGI-I score of 1 [very much improved] or 2 [much improved]) at Weeks 4, 8, 12, and 16", 
                "safety_issue": "No", 
                "time_frame": "Weeks 4, 8, 12, and 16"
            }, 
            {
                "measure": "PSP Total Score change from baseline to Week 16", 
                "safety_issue": "No", 
                "time_frame": "Week 16"
            }, 
            {
                "measure": "SLOF Total Score change from baseline to Week 16", 
                "safety_issue": "No", 
                "time_frame": "Week 16"
            }, 
            {
                "measure": "PSQI Total Score change from baseline to Week 16", 
                "safety_issue": "No", 
                "time_frame": "Week 16"
            }, 
            {
                "measure": "TSQM Total Score change from baseline to Week 16", 
                "safety_issue": "No", 
                "time_frame": "Week 16"
            }, 
            {
                "measure": "Go/No-Go task change from baseline to Week 16", 
                "safety_issue": "No", 
                "time_frame": "Week 16"
            }, 
            {
                "measure": "Delay Discounting task - MCQ scores change from baseline to Week 16", 
                "safety_issue": "No", 
                "time_frame": "Week 16"
            }, 
            {
                "measure": "Delay Discounting task - EDT scores change from baseline to Week 16", 
                "safety_issue": "No", 
                "time_frame": "Week 16"
            }, 
            {
                "measure": "BIS-11 change from baseline to Week 16", 
                "safety_issue": "No", 
                "time_frame": "Week 16"
            }
        ], 
        "source": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}